Sign up USA
Proactive Investors - Run By Investors For Investors

Hikma Pharmaceuticals posts loss after US write-down

Hikma has shed two-thirds of its value over the past year due to product setbacks and a profit warning in August
inhaler
Glaxo can breathe easier for a few more years

Hikma Pharmaceuticals PLC (LON:HIK) slumped into a loss as it wrote down the value of the West-Ward Columbus acquisition by more than US$1bn.

The move marked yet another disappointment for the generic drug manufacturer, which has shed two-thirds of its value over the past year due to product setbacks and a profit warning.

READ: Hikma Pharmaceuticals and Vectura hit by US regulatory setback

Earlier this week, an alternative to GlaxoSmithKline’s Advair asthma inhaler that was being developed with Vectura was rejected by the US Food and Drug Administration until at least 2020.

Losses in 2017 were US$738mln (US$210mln profit), with sales also lower at US$1.94bn.

Core profit fell 9% to US$328mln as operating margin fell to 19.9% from 21.5% reflecting lower profitability in the Generics and Injectables businesses.

Going forward, Hikma said Injectable division revenues will be flat in 2018, Generic sales will fall while Branded products will see mid-single digits growth.

Jordan–based Hikma added that cash generation had been a record over the year and the annual dividend rises to 34c from 33c.

West-Ward Columbus was acquired in 2016 for US$2.65bn.

Shares rose 8% to 940p as brokers said the core profit was well ahead of some of the gloomier forecasts beforehand, while after their heavy fall there was not much downside left.

-- adds share price--

View full HIK profile View Profile

Hikma Pharmaceuticals Timeline

Related Articles

Graphic of person pointing to different parts of the body
May 14 2018
Paradigm’s share price has increased more than 60% in the last month and it was up more than 12% on Friday.
scientist with vial
August 09 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
Dog skeleton with cannabis plant leaf
July 16 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use